Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
B cells as biomarkers: predicting immune checkpoint therapy adverse events
Shannon M. Liudahl, Lisa M. Coussens
Shannon M. Liudahl, Lisa M. Coussens
Published January 8, 2018
Citation Information: J Clin Invest. 2018;128(2):577-579. https://doi.org/10.1172/JCI99036.
View: Text | PDF
Commentary

B cells as biomarkers: predicting immune checkpoint therapy adverse events

  • Text
  • PDF
Abstract

Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-related toxicities that result in a myriad of side effects, ranging from mild and manageable to severe and debilitating. In this issue of the JCI, Das and colleagues report an association between early therapy-induced changes in circulating B cells and an increased risk of high-grade immune-related adverse events (IRAEs) in patients treated with checkpoint inhibitors that target cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and programmed cell death protein 1 (PD1). These findings identify potential predictive biomarkers for high-grade IRAEs that may be leveraged to improve patient monitoring and may prompt new treatment strategies to prevent IRAEs.

Authors

Shannon M. Liudahl, Lisa M. Coussens

×

Figure 1

Changes in circulating B cells predict IRAE risk in patients receiving combined anti-CTLA4 and anti-PD1 therapy.

Options: View larger image (or click on image) Download as PowerPoint
Changes in circulating B cells predict IRAE risk in patients receiving c...
Patients showing changes in circulating B cells after one cycle of combination anti-CTLA4 and anti-PD1 therapy (compared with their pretreatment baseline) have an increased risk of developing high-grade IRAEs. Specifically, a post-treatment reduction in total peripheral B cells and a coincident enrichment of differentiated CD21lo PD1+ memory B cells and plasmablasts correlate with subsequent IRAE development. B cell changes are a unique immune biomarker of IRAE risk, as early changes in the frequency of other circulating leukocyte populations were not detected after therapy (data not shown). Select high-grade IRAE pathologies associated with combined anti-CTLA4 and anti-PD1 mAb therapy are depicted, and patients who showed B cell changes had a median three-week time to onset of one or more such IRAEs.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts